Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid

Investopedia

13 Jan

Key Takeaways

Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.
The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.
Biogen already owns a 10.2% stake in Sage.

Sage Therapeutics (SAGE) shares soared nearly 40% Monday on news Biogen (BIIB) is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.

The unsolicited, non-binding proposal was a 30% premium over Sage’s Friday closing price of $5.55.

The biopharmaceutical firm said its board "will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders."

Biogen Owns 10.2% Stake in Sage

According to a regulatory filing, Biogen owns 6.24 million shares of Sage, equal to a 10.2% stake.

The bid came just as both companies were set to make presentations at this year's J.P. Morgan Healthcare conference in San Francisco.

Despite today's big jump, shares of Sage Therapeutics have lost nearly three-quarters of their value over the past year. Biogen shares slipped less than 1% Monday morning.

TradingView

Do you have a news tip for Investopedia reporters? Please email us at

tips@investopedia.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503589820"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503589820\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503589820?lang=en_US&edition=fundamental","thumbnail":"https://www.investopedia.com/thmb/q9_MAdxlQyU1CGKdgYB_VgASepU=/2872x1915/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1742678123-25d92008a8844f64a3b09d5739a8612f.jpg","is_english":true,"pubTime":"2025-01-13 22:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503589820","market":"us","top_or_hot":-1,"title":"Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid","media":"Investopedia","content":"<html><body><div><div><div><h3>Key Takeaways</h3>\n<div><ul><li><a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.</li><li>The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.</li><li>Biogen already owns a 10.2% stake in Sage.</li></ul></div></div></div>\n<p> Sage <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SAGE) shares soared nearly 40% Monday on news Biogen (BIIB) is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.<span></span>\n</p>\n<div></div>\n<p> The unsolicited, non-binding proposal was a 30% premium over Sage’s Friday closing price of $5.55.\n</p>\n<div></div>\n<p> The biopharmaceutical firm said its board \"will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders.\"\n</p>\n<div></div>\n<span></span><h2> <span> Biogen Owns 10.2% Stake in Sage </span> </h2>\n<p> According to a regulatory filing, Biogen owns 6.24 million shares of Sage, equal to a 10.2% stake.<span></span>\n</p>\n<div></div>\n<p> The bid came just as both companies were set to make presentations at this year's J.P. Morgan Healthcare conference in San Francisco.<span></span>\n</p>\n<div></div>\n<p> Despite today's big jump, shares of Sage Therapeutics have lost nearly three-quarters of their value over the past year. Biogen shares slipped less than 1% Monday morning.\n</p>\n<div></div>\n<figure> <div>\n<div>\n<img height=\"811\" width=\"1542\"/>\n<noscript>\n<img height=\"811\" sizes=\"750px\" src=\"https://www.investopedia.com/thmb/JT4Byri3xjsY5Go2e7dJMU06Ef8=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/SAGE_2025-01-13_09-34-27-5507f125057c4736a6c73d8fdd78e7bc.png\" srcset=\"https://www.investopedia.com/thmb/Xi7IbI4pjCDujuyIgaRQd5zBzyw=/750x0/filters:no_upscale():max_bytes(150000):strip_icc()/SAGE_2025-01-13_09-34-27-5507f125057c4736a6c73d8fdd78e7bc.png 750w\" width=\"1542\"/>\n</noscript>\n</div> </div>\n<figcaption> <span><p>TradingView</p></span>\n</figcaption></figure>\n<div><div>Do you have a news tip for Investopedia reporters? Please email us at</div>\n<span>tips@investopedia.com</span></div></div></body></html>","source":"investopedia_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-13 22:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investopedia.com/sage-therapeutics-stock-soars-as-biogen-makes-unsolicited-takeover-bid-8773323><strong>Investopedia</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Takeaways\nSage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.The bid of $7.22 per share was a 30% ...</p>\n\n<a href=\"https://www.investopedia.com/sage-therapeutics-stock-soars-as-biogen-makes-unsolicited-takeover-bid-8773323\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SAGE","symbol_name":"Sage Therapeutics","start_time":0,"source_url":"https://www.investopedia.com/sage-therapeutics-stock-soars-as-biogen-makes-unsolicited-takeover-bid-8773323","article_id":"2503589820","we_media_id":null,"thumbnails":["https://www.investopedia.com/thmb/q9_MAdxlQyU1CGKdgYB_VgASepU=/2872x1915/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1742678123-25d92008a8844f64a3b09d5739a8612f.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503589820","pubTimestamp":1736779881,"columns":[],"sourceInfo":{"source_id":"investopedia_highlight","name":"Investopedia"},"weMediaInfo":null,"summary":"Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.Biogen already owns a 10.2% stake in Sage.Sage Therapeutics  shares soared nearly 40% Monday on news Biogen  is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.The unsolicited, non-binding proposal was a 30% premium over Sage’s Friday closing price of $5.55.The biopharmaceutical firm said its board \"will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders.\". According to a regulatory filing, Biogen owns 6.24 million shares of Sage, equal to a 10.2% stake.Despite today's big jump, shares of Sage Therapeutics have lost nearly three-quarters of their value over the past year. Biogen shares slipped less than 1","collect":0,"end_time":0,"defaultTopTitle":"investopedia.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SAGE":"Sage Therapeutics","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BIIB":"渤健公司","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4532":"文艺复兴科技持仓","LU0234570918.USD":"高盛全球核心股票组合Acc Close"},"translate_title":"Biogen主动提出收购要约，Sage Therapeutics股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1,"SAGE":1},"content_text":"Key Takeaways\nSage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.Biogen already owns a 10.2% stake in Sage.\n Sage Therapeutics (SAGE) shares soared nearly 40% Monday on news Biogen (BIIB) is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.\n\n\n The unsolicited, non-binding proposal was a 30% premium over Sage’s Friday closing price of $5.55.\n\n\n The biopharmaceutical firm said its board \"will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders.\"\n\n\n  Biogen Owns 10.2% Stake in Sage  \n According to a regulatory filing, Biogen owns 6.24 million shares of Sage, equal to a 10.2% stake.\n\n\n The bid came just as both companies were set to make presentations at this year's J.P. Morgan Healthcare conference in San Francisco.\n\n\n Despite today's big jump, shares of Sage Therapeutics have lost nearly three-quarters of their value over the past year. Biogen shares slipped less than 1% Monday morning.\n\n\n \n\n\n\n\n\n \n TradingView\n\nDo you have a news tip for Investopedia reporters? Please email us at\ntips@investopedia.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1}}}